Pacira Pharmaceuticals (PCRX)

Add to Watchlists Create an Alert
29.30 -0.43  -1.45%   NASDAQ May 24, 8:00PM BATS Real time Currency in USD

Pacira Pharmaceuticals SG&A Expense Quarterly:

13.36M for Dec. 31, 2012
View Full Chart

Pacira Pharmaceuticals SG&A Expense Quarterly Chart

    Pacira Pharmaceuticals Historical SG&A Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 13.36M
    Sept. 30, 2012 11.38M
    June 30, 2012 10.41M
    March 31, 2012 11.15M
    Dec. 31, 2011 7.199M
    Sept. 30, 2011 4.972M
    June 30, 2011 4.466M
       
    March 31, 2011 3.523M
    Dec. 31, 2010 2.419M
    Sept. 30, 2010 1.694M
    June 30, 2010 1.238M
    March 31, 2010 1.011M
    Dec. 31, 2009 1.10M
    Sept. 30, 2009 1.591M

    About SG&A Expense

    SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

    The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
    Learn More

    Get data for

    PCRX SG&A Expense Quarterly Benchmarks

    Companies
    BioScrip 52.79M
    Neurocrine Biosciences 3.392M
    Lannett Company 5.245M

    PCRX SG&A Expense Quarterly Rankings

    Overall 66th percentile
    2653 of 8011
    Sector 66th percentile
    232 of 687 in Healthcare
    Industry 70th percentile
    16 of 55 in Drug Manufacturers - Major

    PCRX SG&A Expense Quarterly Range, Past 5 Years

    Minimum 1.011M Mar 2010
    Maximum 13.36M Dec 2012
    Average 5.394M